Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the Studies of Left Ventricular Dysfunction (SOLVD)
American Heart JournalPublished 1 November 1999
Eric L. Knight, Robert J. Glynn, Kevein M. McIntyre, Helen Mogun, Jerry Avorn
Citations165
SJR quartileQ1
SJR score2.04
SNIP1.18
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF, and older age, diuretic therapy, and diabetes were associated with decreases renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.
Abstract
Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF. Diuretic use and advanced age increased this risk. Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group. beta-Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy.
Keywords
Medicine
Springer series in statisticsNonparametric Estimation from Incomplete Observations
45,533 Citations1992Edward L. Kaplan, Paul Meier
Journal of the Royal Statistical Society Series B (Statistical Methodology)Regression Models and Life-Tables
39,259 Citations1972D. R. Cox
Journal of the American Statistical AssociationNonparametric Estimation from Incomplete Observations
39,052 Citations1958Edward L. Kaplan, Paul Meier
New England Journal of MedicineEffect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
8,006 Citations1991The SOLVD Investigators*
The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions.
New England Journal of MedicineThe Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
5,377 Citations1993Edmund J. Lewis, Lawrence G. Hunsicker +2 more
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
New England Journal of MedicineEffects of Enalapril on Mortality in Severe Congestive Heart Failure
5,077 Citations1987The Consensus Trial Study Group*
It is concluded that the addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms and a significant improvement in NYHA classification was observed in the enAlapril group.
The American Journal of CardiologyEffects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
3,778 Citations1988Karl Swedberg, John Kjekshus
The addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms, and the effect seems to be due to a reduction in death from progression of heart failure.
The LancetRandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
1,660 Citations1997Bertram Pitt, Robert Segal +8 more
Treatment with losartan was associated with an unexpected lower mortality than that found with captopril in older heart-failure patients and there was no difference in renal dysfunction.
JAMAOverview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials
1,538 Citations1995R. Garg
Reductions for total mortality and the combined endpoint were similar for various subgroups examined, but patients with the lowest ejection fraction appeared to have the greatest benefit.
JAMAOverview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure
1,379 Citations1995Rekha Garg
Total mortality and hospitalization for congestive heart failure are significantly reduced by ACE inhibitors with consistent effects in a broad range of patients.
The LancetRandomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
516 Citations1997Nish Chaturvedi
Lisinopril slows the progression of renal disease in normotensive IDDM patients with little or no albuminuria, though greatest effect was in those with microalbuminuria (AER ≥20 μg/min), and the results show that lisinoprill does not increase the risk of hypoglycaemic events in IDDM.
Annals of Internal MedicineEffect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease
429 Citations1997Ioannis Giatras, Joseph Lau +1 more
Neither the magnitude of the beneficial effect nor the safety of ACE inhibition was established conclusively, and it remains uncertain whether ACE inhibitors are preferable to other antihypertensive agents in the treatment of nondiabetic renal disease.
Archives of Internal MedicineLong-term Renoprotective Effect of Angiotensin-converting Enzyme Inhibition in Non—insulin-dependent Diabetes Mellitus
314 Citations1996Mordchai Ravid
Angiotensin-converting enzyme inhibition offers long-term protection against the development of nephropathy in normotensive patients with noninsulin-dependent diabetes mellitus who have microalbuminuria, and it stabilizes renal function in previously untreated patients with impaired renal function.
Kidney InternationalRenal function in the elderly: Impact of hypertension and cardiac function
275 Citations1997Danilo Fliser, Edward Franek +4 more
The results document that the decrease in renal hemodynamics with senescence is less marked than suggested by some studies using less stringent methodology and inclusion criteria and that confounding factors such as hypertension or atherosclerosis confound renal function in the elderly.
Annals of Internal MedicineFunctional Renal Insufficiency During Long-Term Therapy with Captopril and Enalapril in Severe Chronic Heart Failure
216 Citations1987Milton Packer, Carolina Oi Lam Ung +3 more
The deterioration of renal function after converting-enzyme inhibition in heart failure is not a toxic or immunologic reaction to therapy but results from specific hemodynamic events that can be ameliorated by sodium repletion.
The American Journal of CardiologyStudies of Left Ventricular Dysfunction (SOLVD)—Rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction
186 Citations1990The SOLVD Investigators
The rationale and design of a tiered approach to clinical trials that are large enough to provide reliable information on mortality and morbidity, yet provide relevant information on other endpoints are described.
The LancetRisk of morbidity from renovascular disease in elderly patients with congestive cardiac failure
176 Citations1998P. MacDowall, P A Kalra +4 more
Some elderly patients with occult renovascular disease on ACE inhibitors will be at risk of developing uraemia and Renal function should be closely monitored to detect any deterioration early.
Archives of Internal MedicineNational Patterns of Angiotensin-Converting Enzyme Inhibitor Use in Congestive Heart Failure
157 Citations1997Randall S. Stafford
The low rates of use of ACE inhibitors in patients with CHF and the wide variations in their use suggest a need to move beyond clinical trials and focus attention on modifying physician practices.
American Heart JournalAdverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)
156 Citations1996John B. Kostis, Brent J. Shelton +10 more
Enalapril is well tolerated by patients with LVD; however, hypotension, azotemia, cough, fatigue, and other side effects result in discontinuation of therapy in a significant minority of patients.
Archives of Internal MedicineHeart Failure Treatment With Angiotensin-Converting Enzyme Inhibitors in Hospitalized Medicare Patients in 10 Large States
100 Citations1997
International Journal of CardiologyWhy are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?
97 Citations1997Andrew R Houghton, Alan Cowley
An anonymous questionnaire survey of general practitioners in the Nottingham Health District found that although 39.3% of respondents underestimated the poor prognosis associated with heart failure, 98% were aware of the prognostic benefits conferred by angiotensin converting enzyme inhibitors.
PubMedRenal failure related to angiotensin-converting enzyme inhibitors.
76 Citations1997Stephen C. Textor
Under some circumstances when afferent blood supply is compromised, particularly beyond a renal arterial stenosis, use of angiotensin-converting enzyme (ACE) inhibitors can lead to decrements of glomerular filtration rate (GFR) and impaired potassium excretion, which clinicians should be prepared to identify and manage.
American Journal of Kidney DiseasesA Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Enalapril in Patients With Clinical Diabetic Nephropathy
70 Citations1992John H. Bauer, Garry P. Reams +5 more
In the absence of changes in blood pressure, the addition of an ACE inhibitor to patients with clinical diabetic nephropathy could not be shown to confer a unique renal protective effect.
Nephrology Dialysis TransplantationAcute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis
65 Citations1992Frank Bridoux, Marc Hazzan +5 more
DiabetologiaCaptopril and atenolol are equally effective in retarding progression of diabetic nephropathy
55 Citations1994L.D. Elving, Jack F.M. Wetzels +3 more
It is concluded that, in this 2-year study, captopril and atenolol are equally effective in retarding progression of diabetic nephropathy.
Journal of Internal MedicineDeterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible
54 Citations1992Michael Devoy, Charles Tomson +3 more
It is concluded that angiotensin converting enzyme inhibitors should be used with great care in patients in whom atherosclerotic vascular disease is likely and may be responsible for irreversible decrements in renal function.
PubMedAre angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
50 Citations1997G G van Essen, A J Apperloo +5 more
It is concluded that the use of ACE inhibitors is not imperative in all patients with non-diabetic nephropathy because a higher baseline GFR, a greater decrease in GFR and inproteinuria during titration and a lower proteinuria during follow up were independently related to a better GFR slope.
PubMedDiuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure.
44 Citations1994Mandal Ak, Ronald J. Markert +3 more
Whether ACE inhibitors alone produce ARF or whether they do so when used in combination with diuretics is examined, which shows CHF patients had a higher rate of ARF than patients with other diagnoses.
American Heart JournalTolerability of enalapril initiation by patients with left ventricular dysfunction: Results of the medication challenge phase of the studies of left ventricular dysfunction
43 Citations1994John B. Kostis, Brent J. Shelton +9 more
In conclusion, enalapril is well tolerated by patients with left ventricular dysfunction; treatment can be initiated on an outpatient basis in the majority of patients.
Journal of Pharmacology and Experimental TherapeuticsChronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats.
43 Citations1996Frank C. Barone, Adrián Nelson +6 more
Both beta adrenoceptor blockers, especially carvedilol to a considerably greater degree, convey significant protection in a genetic model of severe hypertension that results in renal and cardiovascular organ pathology, neurobehavioral deficits and premature death.
Journal of the American Geriatrics SocietyMeasured versus Estimated Creatinine Clearance in a High‐Functioning Elderly Sample: MacArthur Foundation Study of Successful Aging
41 Citations1993Lynda C. Malmrose, Shelly L. Gray +5 more
To assess the validity of several equations for estimating creatinine clearance in a large sample of high‐functioning, community‐dwelling elderly, several equations were found to be valid.
Drug SafetyACE Inhibitors Drug Interactions of Clinical Significance
41 Citations1995Christian Mignat, Thomas Unger
There is some evidence, albeit scant, linking ACE inhibitors with the induction of lithium toxicity in patients maintained on lithium, and with the occurrence of severe hypersensitivity reactions in patients undergoing haemodialysis, venom immunisation or concomitant allopurinol therapy.
The American Journal of CardiologyAngiotensin-converting enzyme inhibitors and renal function in heart failure
33 Citations1992Rainer Dietz, F Nagel +1 more
Development of functional renal insufficiency is unlikely and is a rare cause for withdrawing ACE inhibitors when certain precautions are considered.
PubMedRenal insufficiency due to angiotensin-converting enzyme inhibitors.
33 Citations1994Robert D. Toto
The decision to pursue testing for RAS should be done on an individual basis; moreover, it is imperative that patient willingness to undergo invasive procedures including angioplasty and/or surgery should be determined prospectively.
CardiologyIdentification of Risk Factors Predisposing to the Development of Functional Renal Insufficiency during Treatment with Converting-Enzyme Inhibitors in Chronic Heart Failure <sup>1</sup>
23 Citations2008Milton Packer
In randomized studies, renal insufficiency developed more frequently with enalapril and lisinopril than with captopril, and the risk of worsening azotemia is particularly high in patients with the most severe (class IV) heart failure.
The American Journal of CardiologySafety of long-term use of lisinopril for congestive heart failure
18 Citations1992Christopher Moyses, Trevor J.C. Higgins
Evaluation of the safety of lisinopril compared with enalapril, captopril, and digoxin in controlled clinical trials shows all the angiotensin-converting enzyme inhibitors to be equally well tolerated with a closely similar range of adverse events, suggesting that the satisfactory safety profile of lisiopril is shared by other drugs of this class.
American Heart JournalDeterminants of the renal response to ACE inhibition in patients with congestive heart failure
12 Citations1992Stephen S. Gottlieb, Shawn Robinson +3 more
It is concluded that poor renal function does not increase the risk of renal deterioration with quinapril, however, dependence of renal function upon the renin-angiotensin system may be predicted by a high filtration fraction.
Cardiovascular Drugs and TherapyPrediction of renal impairment in elderly patients with congestive heart failure treated with captopril
5 Citations1996Doron Schwartz, Ran Kornowski +7 more
Measurement of pretreatment PRA levels might be a useful laboratory tool for predicting the renal safety of captopril use in patients with CHF whose EF ≥30%.